

1987 No. 66

**DANGEROUS DRUGS****Misuse of Drugs (Designation) Order  
(Northern Ireland) 1987***Made* . . . . . 18th February 1987*Coming into operation* . . . . . 1st April 1987

The Department of Health and Social Services in exercise of the powers conferred by section 7(4) and (5) of the Misuse of Drugs Act 1971(a) as adapted by section 7(9) of the Act and now vested in it(b) and of every other power enabling it in that behalf and on the recommendation of the Advisory Council on the Misuse of Drugs, hereby makes the following Order:—

*Citation and commencement*

1. This Order may be cited as the Misuse of Drugs (Designation) Order (Northern Ireland) 1987 and shall come into operation on 1st April 1987.

*Interpretation*

2. The Interpretation Act (Northern Ireland) 1954(c) shall apply to this Order as it applies to a Measure of the Northern Ireland Assembly.

*Designation*

3.—(1) The controlled drugs specified in Part I of the Schedule are hereby designated as drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies.

(2) Part II of the Schedule shall have effect for the purpose of specifying those controlled drugs which are excepted from Part 1.

*Revocations*

4. The Misuse of Drugs (Designation) Order (Northern Ireland) 1977(d) and the Misuse of Drugs (Designation) (Variation) Order (Northern Ireland) 1984(e) are hereby revoked.

Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on 18th February 1987.

(L.S.)

*Z. I. Davies*

Under Secretary

(a) 1971 c. 38

(b) S.R. &amp; O. (N.I.) 1973 No. 504 art. 5(a)

(c) 1954 c. 33 (N.I.)

(d) S.R. 1977 No. 291

(e) S.R. 1984 No. 364

## SCHEDULE

## PART I

CONTROLLED DRUGS TO WHICH SECTION 7(4) OF THE MISUSE OF DRUGS ACT  
1971 APPLIES

1. The following substances and products, namely:—

- |     |   |  |
|-----|---|--|
| (a) | Bufotenine<br>Cannabinol<br>Cannabinol derivatives<br>Cannabis<br>Cannabis resin<br>Cathinone<br>Coca leaf<br>Concentrate of poppy-straw<br>Eticyclidine<br>Lysergamide | Lysergide and other <i>N</i> -alkyl<br>derivatives of lysergamide<br>Mescaline<br>Psilocin<br>Raw opium<br>Rolicyclidine<br>Tenocyclidine<br>4-Bromo-2,5-dimethoxy- $\alpha$ -methyl-<br>phenethylamine<br><i>N,N</i> -Diethyltryptamine<br><i>N,N</i> -Dimethyltryptamine<br>2,5-Dimethoxy- $\alpha$ ,4-dimethyl-<br>phenethylamine |
|-----|---|--|
- (b) any compound (not being a compound for the time being specified in sub-paragraph (a)) structurally derived from tryptamine or from a ringhydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- (c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a)) structurally derived from phenethylamine, an *N*-alkylphenethylamine,  $\alpha$ -methylphenethylamine, an *N*-alkyl- $\alpha$ -methylphenethylamine,  $\alpha$ -ethylphenethylamine, or an *N*-alkyl- $\alpha$ -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (d) any compound (not being a compound for the time being specified in Part II) structurally derived from fentanyl by modification in any of the following ways, that is to say,
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
  - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
  - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
  - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
  - (v) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or acyloxy group;
  - (vi) by replacement of the *N*-propionyl group by another acyl group;
- (e) any compound (not being a compound for the time being specified in Part II) that is structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
  - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propiono bridge, whether or not further substituted;

- (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
  - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxyalkyl or acyloxy group;
  - (v) by formation of an *N*-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1.
  3. Any ester or ether of a substance specified in paragraph 1 or 2.
  4. Any salt of a substance specified in any of paragraphs 1 to 3.
  5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4.

## PART II

## CONTROLLED DRUGS EXCEPTED FROM PART I

1. The compounds referred to in paragraph 1(*d*) of Part I are—

Alfentanil  
Carfentanil  
Lofentanil  
Sufentanil.

2. The compounds referred to in paragraph 1(*e*) of Part I are—

Allylprodine  
Alphameprodine  
Alphaprodine  
Anileridine  
Betameprodine  
Betaprodine  
Hydroxypethidine  
Properidine  
Trimeperidine.

## EXPLANATORY NOTE

*(This note is not part of the Order.)*

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under the Act. Section 7(3) does not however apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order, which replaces the Misuse of Drugs (Designation) Order (Northern Ireland) 1977, as amended, designates for this purpose the drugs specified in Part I of the Schedule to the Order. It differs from the previous Order by the addition, in paragraph 1 of Part I, of Cathinone in sub-paragraph (a) and two new sub-paragraphs (d) and (e), which relate, respectively, to certain fentanyl derivatives and certain pethidine derivatives.

Part II of the Schedule specifies certain compounds which are excepted from paragraph 1(d) and (e) of Part I and are therefore not designated by this Order.